Via News Knowledge File
BioNTech SE
organization80% conf.·synced Aug 13, 2026
Biotechnology company involved in patent litigation with Moderna
30
sourced metrics
482
relationships
20
stated objectives
0
Via News reports
Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →
Key metrics · each point sourced
Clinical Programs
17programs
Parameter Count
6asco_2026_presentations
May 22, 2026source
Shareholder Attendance
92percent
May 15, 2026source
Supervisory Board Size
8members
May 15, 2026source
Combination Therapy Trials
5trials
Mar 24, 2026source
Ongoing Clinical Trials
16trials
Mar 24, 2026source
Ongoing Novel Novel Combination Trials
5trials
Mar 24, 2026source
Active Lung Cancer Trials
16trials
Mar 24, 2026source
Phase 3 Trials
4trials
Mar 24, 2026source
Ongoing Phase3 Trials
4trials
Mar 24, 2026source
Company Age
18years
Mar 10, 2026source
Novel Novel Combination Trials
10trials
Jan 12, 2026source
Phase 2 3 Trials Count
25trials
Jan 12, 2026source
Combination Therapy Trials Count
10trials
Jan 12, 2026source
Phase 3 Trials Count
15trials
Jan 12, 2026source
Phase 2 3 Trials
25trials
Jan 12, 2026source
Cash
17.2USD
Dec 31, 2025source
Revenue
2.6-2.8billion_EUR
Nov 30, 2025⚠ sources conflictsource
Stated objectives
2025 SG&A expenses target
sourcetarget: $550M-$650M by 2025-12-31 00:00:00stated
2025 CapEx for operations target
sourcetarget: $200M-$250M by 2025-12-31 00:00:00stated
Transition to fully integrated commercial oncology company
sourceby 2025-12-31 00:00:00stated
2025 R&D expenses target
sourcetarget: EUR 2.0B-EUR 2.2B by 2025-12-31 00:00:00stated
Achieve FY 2025 revenue between €2,600M and €2,800M
sourcetarget: 2600-2800 by 2025-12-31 00:00:00stated
Reduce R&D costs to €2,000-2,200M for FY 2025
sourcetarget: 2000-2200 by 2025-12-31 00:00:00stated
Reduce SG&A costs to €550-650M for FY 2025
sourcetarget: 550-650 by 2025-12-31 00:00:00stated
Reduce CapEx to €200-250M for FY 2025
sourcetarget: 200-250 by 2025-12-31 00:00:00stated
File BLA for Trastuzumab Pamirtecan in 2026 pending FDA feedback
sourceby 2026-12-31 00:00:00stated
Initiate ROSETTA Breast-01 Phase 3 trial for TNBC by end of 2025
sourceby 2025-12-31 00:00:00stated
Relationship graph · 482 connections
Developed by
103
Partnered with
85
Employs
52
Partners with
35
Invested in
34
founded
29
headquartered in
23
Customer of
21
Partners with
headquartered in
regulated by
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →